Statutory & financial benchmarks
| Category | Where it may be prepared | Maximum BUD | Relevance to IV hydration |
|---|---|---|---|
| Immediate-use CSP | Outside a classified area, with aseptic technique | Administration begins within 4 hours of the start of preparation | The provision most lounges and mobile nurses rely on |
| Category 1 | ISO Class 5 PEC in a segregated compounding area | ≤ 12 hours at 20–25 °C; ≤ 24 hours at 2–8 °C | Clinics with a certified hood but no cleanroom suite |
| Category 2 | ISO 5 PEC inside an ISO 7 buffer room with ante-room | Sterile starting components, no sterility test: 4 days room, 10 days fridge, 45 days frozen | Pharmacy-grade operations; rare in clinics |
| Category 2 (sterility tested) | Same cleanroom suite, passed sterility testing | 30 days room, 45 days fridge, 60 days frozen | Pharmacies preparing batches |
| Category 3 | Category 2 suite plus additional testing, garbing and monitoring | Aseptic and sterility tested: up to 60 days room, 90 days fridge, 120 days frozen | Large compounders; clinics buy these products, they do not make them |
What counts as compounding at an IV clinic
USP <797> defines compounding broadly: combining, admixing, diluting, pooling or reconstituting a sterile drug other than as the manufacturer’s labeling directs. Injecting magnesium chloride, B-complex and ascorbic acid into a bag of 0.9% sodium chloride is compounding. So is pre-filling syringes for later use.
Some activities fall outside the chapter. Administration itself (spiking a manufactured bag of Lactated Ringer’s and running it) is not compounding. Preparing a single conventionally manufactured product exactly as its approved labeling directs, for one patient and not for storage, is also outside the definition. The moment you combine products, or prepare ahead, you are inside <797>.
USP chapters become enforceable through state law. Most boards of pharmacy, and in many states the medical and nursing boards, adopt <797> by reference, and some add requirements of their own. FDA can also act against compounding performed under insanitary conditions.
The immediate-use provision, condition by condition
The 2023 revision, official on November 1, 2023, kept the immediate-use exemption but rewrote it. All of the following must be true:
- No more than 3 different sterile products are combined. Boards and consultants commonly count the carrier bag itself as one of the three.
- Administration begins within 4 hours of the start of preparation. The infusion does not have to finish within 4 hours, but it must have started. The previous version of the chapter allowed only 1 hour.
- Aseptic technique is followed, and the person preparing it has been trained and has demonstrated competency in aseptic processes, under written procedures.
- Compatibility is supported by evidence-based information such as labeling or a recognized compatibility reference.
- Single-dose containers are used for one patient only, and any unused portion is discarded after the preparation is complete.
- Labeling: unless the preparer administers it immediately, or witnesses its immediate and complete administration, the CSP is labeled with patient identification, the names and amounts of all components, the preparer’s name or initials, and the 4-hour time limit.
Where real drip formulas fall
Count every sterile product that goes into the final preparation, including the bag. The examples below assume the bag counts, which is the conservative and most common reading.
| Preparation | Sterile products | Immediate-use? | Compliant path |
|---|---|---|---|
| 1,000 mL Lactated Ringer’s, nothing added | 1 (administration only) | Not compounding | Spike and hang |
| 500 mL 0.9% NaCl + B-complex + cyanocobalamin | 3 | Yes, if started within 4 hours | Prepare at the bedside for that patient |
| NAD+ (reconstituted vial) + 500 mL 0.9% NaCl | 2 (count the diluent if separate: 3) | Yes, if the infusion starts within 4 hours | Slow titration may run 2–4 hours; only the start time matters |
| Bag + magnesium + B-complex + ascorbic acid | 4 | No | 503B premixed bag, or move a component to a separate push where the protocol allows |
| Classic Myers’-style: bag + magnesium + calcium + B-complex + B12 + B5 + B6 + vitamin C | 6–8 | No | 503B or pharmacy-compounded preparation with a labeled BUD |
| Five bags mixed at 8 a.m. for the day’s bookings | Any | No (batching) | Prepare per patient, or buy 503B premixed bags |
Moving a component to a separate IV push or IM injection is a clinical decision, not a paperwork trick. It needs a protocol the medical director has signed and a push rate that is safe for that agent. For sourcing premixed or multi-ingredient products, see 503A vs 503B pharmacies.
Vials, beyond-use dates and mobile storage
Container rules cause as many findings as mixing rules. Single-dose vials are for one patient; using the rest of a B12 vial on the next client is both a <797> and an injection-safety violation. Multiple-dose vials, once punctured, are generally given a 28-day BUD unless the manufacturer specifies otherwise, and should be dated when opened.
| Item | Rule of thumb | What inspectors check |
|---|---|---|
| Single-dose vial | One patient, discard remainder after preparation | Partially used vials in the kit or fridge |
| Multiple-dose vial | 28 days after first puncture unless labeling says otherwise | Open date and initials on every vial |
| Immediate-use CSP | Administration starts within 4 hours, or discard | Prepared bags waiting in vehicles or prep areas |
| 503B premixed bag | Use within the labeled BUD and storage conditions | Expired lots, temperature excursions |
| Refrigerated stock | 2–8 °C with continuous logging | Data logger records, excursion responses |
Vehicles are the weak point. Read cold chain and mobile storage for logger set-up and excursion handling.
Do you need Category 1 or a cleanroom?
If your formulas exceed three sterile products and you want to prepare them in-house, the next step up is Category 1: an ISO Class 5 primary engineering control (a certified laminar airflow hood or biological safety cabinet) in a segregated compounding area, with a BUD of 12 hours at room temperature or 24 hours refrigerated. Category 1 brings obligations: certification of the hood every 6 months, environmental monitoring, cleaning logs, garbing and personnel competency testing (gloved fingertip sampling and media-fill tests at defined intervals), a designated person responsible for compliance and written SOPs.
Some states also require a pharmacy permit or a specific licence before anyone other than a pharmacist compounds beyond immediate-use. For most hydration practices, buying 503B products is cheaper and safer than building and maintaining a Category 1 operation. Boards in states we classify as high pharmacy enforcement (including California, Texas, Florida, North Carolina, Ohio and Virginia) are the most likely to inspect.
Surviving a board of pharmacy inspection
Inspections of IV clinics often follow a complaint or an adverse event. Inspectors walk the preparation area, open the refrigerator and the nurse’s kit, and pull records. Have these ready:
- Written compounding SOPs that state you prepare only immediate-use CSPs, with the 3-product and 4-hour limits spelled out.
- Training and aseptic technique competency records for every person who prepares CSPs.
- Purchase invoices, 503B facility registration evidence and lot numbers that match the stock on hand.
- Temperature logs for every refrigerator and vehicle unit, with documented responses to excursions.
- Charts that record the time preparation started and the time the infusion began.
- Cleaning records for the preparation surface and hand hygiene supplies at the point of preparation.
Run your state through the provider calculator to see its enforcement tier, and use the partner intake to be connected with a 503B supplier.
Step-by-step USP <797> readiness for an IV clinic
- Inventory every formulaList each drip and count its sterile products, including the carrier bag.
- Split the menuFormulas with 3 or fewer products can be immediate-use; the rest need 503B or pharmacy-prepared products.
- Write the SOPImmediate-use limits, aseptic technique steps, labeling, discard rules and what to do if administration is delayed.
- Train and test staffDocument aseptic technique training and competency for every nurse who prepares a CSP.
- Set up a clean preparation zoneA cleanable, uncluttered surface away from sinks and patient traffic, cleaned before each preparation.
- Record timingChart the preparation start time and the infusion start time for every bag.
- Control vialsDiscard single-dose remainders, date multiple-dose vials on opening, and remove expired stock weekly.
- Log temperaturesContinuous data loggers in every refrigerator and vehicle unit, reviewed daily.
- Check state add-onsAsk your board of pharmacy whether your state requires a permit, licence or stricter rules for clinic compounding.
- Run a mock inspectionHave the medical director or a consultant walk the space and pull records twice a year.
Common regulatory audit traps
Counting the bag out
Practices often count only the vials and claim a four-additive drip is immediate-use. Boards commonly count the carrier bag, so a bag plus three additives is four products and out of bounds.
Pre-spiked bags
Bags admixed or spiked in advance for later patients are cited as batching and as compounding outside immediate-use. Prepare at the time of service for the specific patient.
Reusing single-dose vials
Drawing a second patient’s dose from a single-dose vial is one of the most serious findings because it is an infection-transmission risk. Discard the remainder every time.
No timing in the chart
Without a preparation start time there is no evidence the 4-hour limit was met. Make both times mandatory fields.
Gaps in temperature records
Missing logger data for a vehicle fridge means the inspector cannot accept the stock as properly stored. Use continuous loggers and keep excursion notes.
Category 1 claims without the controls
A hood that has not been certified in the last 6 months, or no environmental monitoring, means the clinic is not Category 1 regardless of the equipment on the counter.
Run your state’s compliance and margin model
Pick your state, licence, model and volume to see the required entity structure, medical director retainer, GFE and 503B supply costs, and net margin, then get matched with the network.
State rules that matter most here
Frequently asked questions
What is an immediate-use CSP under USP <797>?
It is a compounded sterile preparation made outside a classified area that involves no more than 3 different sterile products and whose administration begins within 4 hours of the start of preparation. It must be made with aseptic technique by trained staff for one patient.
Does the saline bag count toward the three products?
The bag is a sterile product, and boards and consultants commonly count it toward the limit. Planning on that basis keeps you on the conservative side of an inspection.
When did the revised USP <797> take effect?
The revised chapter became official on November 1, 2023. It introduced Category 1, 2 and 3 CSPs and extended the immediate-use window from 1 hour to 4 hours.
Can a nurse mix a Myers’ cocktail in a patient’s home?
A traditional Myers’-style formula combines six or more sterile products, so it exceeds the immediate-use limit. Practices typically use a 503B premixed preparation or a pharmacy-compounded product instead.
Does the infusion have to finish within 4 hours?
No. The requirement is that administration begins within 4 hours of the start of preparation. A slow NAD+ infusion that starts promptly and runs for several hours meets the timing condition.
Who enforces USP <797> for IV clinics?
Mainly state boards of pharmacy, along with medical and nursing boards in states that adopt the chapter by reference. FDA can also act against drugs prepared under insanitary conditions.
Sources & standards reviewed
- USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations (2023 revision) United States Pharmacopeia
- Human drug compounding and insanitary conditions U.S. Food and Drug Administration
- Injection safety and single-dose / multi-dose vial guidance Centers for Disease Control and Prevention
- Infusion Therapy Standards of Practice Infusion Nurses Society
- State board of pharmacy compounding rules (adoption of USP <797>) National Association of Boards of Pharmacy
Reviewed under the IVConnection clinical and regulatory review policy. Report a correction to clinical@ivconnection.com.